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A b s t r a c t
The ‘prion-like’ transfer of pathogenic proteins may play a role in the pathogenesis of frontotemporal lobar degen-
eration (FTLD). Propagation of such proteins along anatomical pathways may give rise to specific spatial patterns 
of  the  ‘signature’ neuronal cytoplasmic inclusions (NCI) characteristic of  these disorders. Hence, the  spatial pat-
terns of  the NCI were compared in three molecular subtypes of  FTLD: (1) two variants of  FTLD-tau, viz. cortico-
basal degeneration (CBD) and Pick’s disease (PiD), (2) FTLD with transactive response (TAR) DNA-binding protein 43 
(TDP-43)-immunoreactive inclusions (FTLD-TDP), and (3) FTLD with ‘fused in sarcoma’ (FUS)-immunoreactive inclu-
sions (FTLD-FUS). Regardless of molecular pathology, the NCI in the frontal and temporal cortex were most frequent-
ly aggregated into clusters, the clusters being regularly distributed parallel to the pia mater. In a significant propor-
tion of regions, the regularly distributed clusters were in the size range 400–800 μm, approximating the dimension 
of cell columns associated with the cortico-cortical pathways. Clusters of NCI were significantly larger in FTLD-tau 
compared with FTLD-TDP and FTLD-FUS. The data suggest that cortical NCI in different molecular subtypes of FTLD 
all share a similar spatial pattern in the frontal and temporal cortex consistent with a ‘prion-like’ spread of patho-
logical proteins along anatomical pathways. However, a more selective group of neurons appears to be affected in 
FTLD-TDP and FTLD-FUS than in FTLD-tau.
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Introduction
Most cases of frontotemporal lobar degeneration 
(FTLD) can be classified into three molecular subtypes: 
(1) FTLD with tau-immunoreactive inclusions (FTLD-
tau), a heterogeneous group of disorders, examples 
of  which include corticobasal degeneration (CBD), 
Pick’s disease (PiD), and progressive supranuclear 
palsy (PSP), (2) FTLD with transactive response (TAR) 
DNA-binding protein 43 (TDP-43)-immunoreactive 
inclusions (FTLD-TDP), and (3) FTLD with ‘fused in sar-
coma’ (FUS)-immunoreactive inclusions (FTLD-FUS) 
[42]. In all of these disorders, abnormally aggregated 
proteins result in the  formation of  phosphorylated 
‘signature’ neuronal cytoplasmic inclusions (NCI), FUS 
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protein in FTLD-FUS being additionally hypomethylat-
ed [48], most abundantly in the frontal and temporal 
cortex [15,29,52]. 
Many pathogenic proteins can exhibit ‘prion-like’ 
behaviour, i.e., they act as propagating entities or 
‘seeds’ amplifying their pathogenic conformation 
similar to prion protein (PrPsc) in prion diseases 
[35,37]. As a consequence, proteins may spread along 
anatomical pathways and the  clinical phenotype 
of  the disease could depend, in part, on variations 
in this spread and the  specific pathways affected. 
If pathogenic proteins spread along anatomical con-
nections, then the resulting NCI may exhibit a spa-
tial distribution pattern in the cortex which reflects 
this spread [10]. In Creutzfeldt-Jakob disease (CJD), 
in which propagation of  PrPsc along anatomical 
pathways is well documented [19-21], PrPsc depos-
its are clustered in the  cerebral cortex, the  clus-
ters being regularly distributed parallel to the  pia 
mater [11,13]. This pattern of  clustering may there-
fore be a marker for the spread of PrPsc [12,14] and 
other proteins among brain regions along anatomical 
pathways [10]. In  addition, tau and TDP-43 but not 
FUS may share amyloid properties [23] and therefore 
inclusions in FTLD-FUS may have a different spatial 
pattern than in the other subtypes. Hence, the pres-
ent study compared the  spatial patterns of  NCI 
in cases representing the  three subtypes of  FTLD: 
(1) two variants of  FTLD-tau, viz. CBD and PiD, 
(2) FTLD-TDP, and (3) FTLD-FUS. Two main questions 
were addressed: (1) Are the spatial patterns of the NCI 
in the three disorders consistent with the propagation 
of pathological proteins? (2) Did molecular pathology 
influence the spatial patterns of the NCI?
Material and methods
Cases
Demographic data and diagnostic criteria for 
the three molecular subtypes of FTLD are shown in 
Table I. CBD (n = 12) and PiD (n = 10) cases (FTLD-tau) 
were obtained from the  Brain Bank, Department 
of  Neuropathology, Institute of  Psychiatry, King’s 
College, London, UK. FTLD-TDP cases (n = 32) were 
obtained from Washington University, St Louis, MO., 
USA). Of the 32 FTLD-TDP cases, 20 were familial (at 
least one first degree relatives affected) and of these, 
10 cases had GRN mutations [18,22,28,41,43], one 
had a VCP gene mutation, and one case was asso-
ciated with the C90RF72 gene [40,46]. The majority 
(n = 7) of the GRN cases were from a single heredi-
tary dysphasic disinhibition dementia (HDDD) fam-
ily (HDDD2) [43] and the  remainder (n = 3) from 
a HDDD1 family [22]. No genetic defects have been 
identified to date in the remaining eight familial cases 
but none of these had a strong autosomal dominant 
pattern of inheritance. FTLD-FUS cases (n = 10) [16] 
were obtained from centres in Canada, Norway, 
Spain, Japan (one case from each), and from France, 
the UK, and the USA (two cases from each) [25]. 
Tissue preparation
After death, the  consent of  the  next of  kin was 
obtained for brain removal following local Ethical 
Committee procedures and the  1999 Declaration 
of Helsinki (as modified Edinburgh, 2000). Brain tis-
sue was preserved in buffered 10% formalin or 4% 
paraformaldehyde. Tissue blocks were taken from 
frontal and temporal lobe, fixed in 10% phosphate 
buffered formal-saline, and embedded in paraffin 
wax. Immunohistochemistry (IHC) was performed on 
6-8 µm sections using appropriate antibodies (Table I). 
Sections were counterstained with haematoxylin. 
Morphometric methods 
In the superior frontal gyrus (SFG), inferior tem-
poral gyrus (ITG), and parahippocampal gyrus (PHG), 
NCI were counted along a  strip of  tissue (3200 to 
6400 µm in length) located parallel to the pia mater, 
using 250 × 50 µm sample fields arranged contig-
uously [4]. The  sample fields were located both in 
the upper (approximating to layers II/III) and lower 
(approximating to layers V/VI) cortex, the short edge 
of  the  sample field being orientated parallel with 
the pia mater and aligned with guidelines marked 
on the slide. The number of NCI present in each sam-
ple field was counted. 
Data analysis
The data were analysed by spatial pattern analy-
sis [2,4,6,7,9]. This method uses the variance-mean 
ratio (V/M) to determine whether the NCI were dis-
tributed randomly (V/M = 1), regularly (V/M < 1), 
or were clustered (V/M > 1) along a strip of tissue. 
Counts of NCI in adjacent sample fields were added 
together successively to provide data for increasing 
field sizes, e.g., 50 × 250 µm, 100 × 250 µm, 200 × 
250 µm, etc., up to a  size limited by the  length 
of the strip sampled. V/M was plotted against field 
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size to determine whether the clusters of NCI were 
regularly or randomly distributed and to estimate 
the mean cluster size parallel to the  tissue bound-
ary. A V/M peak indicates the presence of regularly 
spaced clusters. The statistical significance of a peak 
was tested using the  ‘t’ distribution [4]. The effect 
of molecular pathology on the frequency of the dif-
ferent types of spatial pattern was tested using chi-
square (Χ2) contingency tables. In  addition, mean 
cluster sizes of NCI were compared between FTLD sub-
types using a one-way analysis of  variance (ANOVA) 
(STATISTICA software, StatSoft Inc., 2300 East 14th St, 
Tulsa, Ok, 74104, USA) followed by Tukey’s HSD 
post-hoc test. 
Results
Examples of the NCI in the three FTLD subtypes 
are shown in Figures 1 and 2. Consistent morpho-
logical differences were apparent among disorders, 
spherical inclusions being predominant in PiD and 
FTLD-FUS, while NCI in CBD and FTLD-TDP were more 
variable, being spherical, spicular, or flame-shaped. 
Examples of  the  spatial patterns of  the  NCI 
observed in a  single brain region (ITG, layers II/III) 
in the  three FTLD subtypes are shown in Figure 3. 
The V/M ratios of the NCI in CBD (FTLD-tau) increased 
with field size without reaching a peak, suggesting 
a large cluster of NCI at least 1600 mm in diameter. 
The V/M ratios of the NCI in FTLD-TDP and FTLD-FUS, 
however, reached peaks at field sizes of 200 mm and 
100 mm respectively, suggesting clusters of  inclu-
sions, 200 mm and 100 mm in diameter, which were 
regularly distributed parallel to the pia mater. 
A comparison of  the  spatial patterns exhibited 
by the NCI in FTLD-tau, FTLD-TDP, and FTLD-FUS in 
all cases and regions is shown in Table II. Most fre-
quently, NCI were clustered and the  clusters were 
regularly distributed parallel to the pia mater. This 
spatial pattern varied in frequency among subtypes 
Table I. Summary of demographic details, diagnostic criteria, and immunohistochemistry (IHC) of the fronto-
temporal lobar degeneration (FTLD) subtypes
Disorder n Age mean (SD) M : F IHC Diagnostic criteria
FTLD-tau (CBD) 12 64.07 (9.07) 8 : 4 TP007 (tau) NIH-ORD
FTLD-tau (PiD) 10 65.03 (11.3) 7 : 3 TP70 (tau) Cairns et al. [26]
FTLD-TDP 32 71.03 (1.62) 16 : 16 pTDP-43 Cairns et al. [26]
FTLD-FUS 10 45.3 (12.1) 7 : 3 FUS Cairns et al. [26]
CBD – corticobasal degeneration, FUS – ‘fused in sarcoma’, PiD – Pick’s disease, TDP-43 – transactive response (TAR) DNA-binding protein 43, n – number 
of cases studied, M – male, F – female. 
Diagnostic criteria: National Institutes of Health – Office of Rare Diseases (NIH-ORD); diagnostic criteria for FTLD-TDP and FTLD-FUS according to Cairns et al. (2007)
Fig. 1. Neuronal cytoplasmic inclusions (NCI) 
in frontotemporal lobar degeneration (FTLD) 
with tau-immunoreactive inclusions (FTLD-tau): 
A) corticobasal degeneration (CBD) (antibody 
TP007, bar = 100 μm) and B) Pick’s disease (PiD)  
(Antibody tau TP70, bar = 50 μm).
A
B
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from 45% of  cortical gyri in FTLD-TDP to 74% in 
FTLD-FUS. Larger-scale clustering, in which the NCI 
occurred in clusters of  at least 1600 mm in diam-
eter, but without regular spacing, was also present 
in some regions. Within FTLD-tau, there were no 
significant differences between the spatial patterns 
of the NCI in CBD and PiD (Χ2 = 2.37, 3DF, p > 0.05) 
and in FTLD-TDP between familial and sporadic cases 
(Χ2 = 3.11, 6DF, p > 0.05). However, there were sig-
nificant differences in the proportions of  the dif-
ferent spatial patterns among FTLD subtypes 
(Χ2 = 65.12, 9DF, p < 0.001), comparisons of the sub-
types in pairs suggesting that FTLD-tau exhibited 
more frequent large-scale clustering than FTLD-TDP 
(Χ2 = 51.15, 3DF, p < 0.001) and FTLD-FUS (Χ2 = 21.47, 
3DF, p < 0.001). In addition, the frequency of random 
distributions was higher in FTLD-TDP. In all subtypes, 
a small number of regions exhibited a more complex 
spatial pattern in which small, regularly distribut-
ed clusters were themselves aggregated into larger 
‘superclusters’.
A comparison of estimated cluster sizes of the NCI 
in the three subtypes is shown in Table III. There was 
a significant difference in mean cluster size among 
subtypes (F = 28.68, p < 0.001), post-hoc tests sug-
gesting that cluster sizes were significantly larger in 
FTLD-tau than in FTLD-TDP and FTLD-FUS. In  addi-
tion, the proportion of cortical regions in which reg-
ularly distributed clusters were within the size range 
400-800 mm varied among subtypes (Χ2 = 7.94, 2DF, 
p < 0.05), FTLD-tau variants exhibiting a greater pro-
portion of regions within this size range (Χ2 = 5.43, 
1DF, p < 0.05) compared with FTLD-TDP and FTLD-
FUS, which exhibited a similar range (Χ2 = 1.42, 1DF, 
p > 0.05).
Discussion 
The data suggest that in all three molecular sub-
types of FTLD, the NCI were clustered in the frontal 
and temporal cortex and, in a significant proportion 
of gyri, the clusters were regularly distributed paral-
lel to the pia mater [13]. The frequency of this spatial 
pattern varied among subtypes, being most frequent 
in FTLD-FUS (74%) and least frequent in FTLD-TDP 
Fig. 2. Neuronal cytoplasmic inclusions (NCI) 
in frontotemporal lobar degeneration (FTLD):  
A) with TDP-43-immunoreactive inclusions (FTLD-
TDP) (antibody pTDP-43, bar = 100 μm) and B) with  
FUS-immunoreactive inclusions (FTLD-FUS) (anti-
body FUS, bar = 100 μm).
Fig. 3. Pattern analysis plots showing examples 
of the spatial patterns exhibited by neuronal 
cytoplasmic inclusions (NCI) in the inferior tem-
poral gyrus (ITG): A comparison of three subtypes 
of frontotemporal lobar degeneration (FTLD), viz. 
FTLD-tau (CBD), FTLD-TDP, and FTLD-FUS (* indi-
cates significant variance/mean peaks).
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(45%). Similar spatial patterns have been observed 
in Alzheimer’s disease (AD) [3,8], in various synucle-
inopathies such as Parkinson’s disease dementia 
(PDD) [10] and in CJD [11,13]. Hence, although FUS 
may not share the amyloid-like properties of tau and 
TDP-43 [23], the  similar spatial patterns exhibited 
suggest that similar pathological processes may be 
present in diseases characterised by different molec-
ular pathologies [34].
The regular distribution of clusters of NCI is con-
sistent with their development in association with 
the cells of origin of specific cortical pathways [3,14]. 
In  cortical regions, these cells are clustered and 
occur in bands which are regularly distributed along 
the cortex. Individual bands of cells traverse the cor-
tical layers and, in the primate brain, vary in width 
from 400-500 mm up to 800-1000 µm depending on 
the region [30,36]. In a proportion of gyri, the width 
of  the  NCI clusters and their distribution along 
the cortex suggest an association with these path-
ways with two exceptions. First, in some gyri, NCI 
occurred in larger clusters greater than 800-1600 mm, 
especially in FTLD-tau, and in some regions, small 
clusters of NCI were aggregated into larger ‘super-
clusters’. These results suggest that the  smaller, 
regularly distributed clusters of  inclusions could 
‘coalesce’ to form larger clusters as the  disease 
develops [3]. Second, NCI were randomly distributed 
in some gyri, especially in FTLD-TDP, which may be 
the result of the low density of pTDP-43-immunore-
active inclusions observed in some cases [15]. 
Differences in cluster sizes of NCI among subtypes 
suggest variation in the degree to which specific cor-
tical columns may be affected by the different molec-
ular pathologies. Hence, significantly larger clusters 
of  NCI were observed in FTLD-tau than in FTLD-
Table II. Frequency of the different types of spatial pattern (R – random, RG – regular) exhibited by neuronal 
cytoplasmic inclusions (NCI) in three subtypes of frontotemporal lobar degeneration (FTLD): FTLD-tau, viz. 
Pick’s disease (PiD), and corticobasal degeneration (CBD), FTLD-TDP, and FTLD-FUS. Data in parentheses 
indicate the number of gyri in which regular clusters of inclusions were in the size range 400-800 μm
Disorder Subtype R RG Regular clusters (50-1600 μm) Large clusters (≥ 1600 μm)
FTLD-tau CBD 2 2 48 (24) 24
PiD 1 0 27 (17) 20
FTLD-TDP All cases 36 17 60 (28) 19
GRN mutation 16 5 23 (11) 5
Non-GRN familial cases 9 4 16 (7) 7
Sporadic cases 11 8 21 (10) 7
FTLD-FUS – 7 3 39 (11) 4
Chi-square (χ2) contingency tests: 
Between subtypes of FTLD-tau: χ2 = 2.37 (3DF, p > 0.05)
Between subtypes of FTLD-TDP: χ2 = 3.11 (6DF, p > 0.05)
All groups: χ2 = 65.12 (9DF, p < 0.001) 
Comparing FTLD-tau and FTLD-TDP: χ2 = 51.15 (3DF, p < 0.001)
Comparing FTLD-tau and FTLD-FUS: χ2 = 21.47 (3DF, p < 0.001)
Comparing FTLD-TDP and FTLD-FUS: χ2 = 12.05 (3DF, p < 0.01)
Table III. Estimated mean cluster sizes (SE – standard error) of the neuronal cytoplasmic inclusions (NCI) 
in the cortex of three subtypes of frontotemporal lobar degeneration (FTLD), viz. FTLD-tau, FTLD-TDP, and 
FTLD-FUS
Subtype Mean cluster size (μm) Range (μm) SE Percentage of gyri in range 400-800 (μm)
FTLD-tau (CBD) 1990 100-1600 243.9 32
FTLD-tau (PiD) 3229 200-1600 385.9 51
FTLD-TDP 302 50-1600 97.2 10
FTLD-FUS 474 50-1600 134.4 21
Comparison of cluster sizes (1-way ANOVA with ‘Tukey HSD’ post-hoc test): Between disorders F = 23.52 (p < 0.001), post-hoc FTLD-tau > FTLD-TDP = FTLD-FUS
Comparison of proportions of regions with cluster sizes in the range 400-800 mm:
All groups χ2 = 7.94 (2DF, p < 0.05)
Comparing FTLD-tau and. FTLD-TDP + FTLD-FUS χ2 = 5.43 (1DF, p > 0.05)
Comparing FTLD-TDP and FTLD-FUS χ2 = 1.42 (1DF, p > 0.05)
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TDP and FTLD-FUS, and in the  latter two disorders 
the clusters were usually smaller than the estimated 
diameter of the cell columns of the cortico-cortical 
projections. Hence, a more localised pattern of cor-
tical degeneration appears to be present in FTLD-
TDP and FTLD-FUS. Compared with tau, which is 
widespread in neurons and important in the assem-
bly and stabilisation of  microtubules [27,51], both 
TDP-43 and FUS have more specific roles, TDP-43 in 
mRNA function, DNA repair, and in non-coding RNA 
metabolism [45] while FUS is important in regulat-
ing gene expression including transcription, splicing, 
and RNA transport [31]. In  both TDP-43 and FUS, 
nuclear clearance results in the  immediate aggre-
gation in the  cytoplasm of  cells [33]. In  addition, 
TDP-43 can also repress non-conserved cryptic axons, 
many of which are cell type specific, and therefore loss 
of  TDP-43 function could result in the  degeneration 
of specific groups of cells [38,39]. 
Of particular interest is whether the  observed 
spatial patterns could reflect the  ‘prion-like’ 
behaviour of pathogenic proteins [32,35,37,47]. Sev-
eral observations are consistent with this hypothe-
sis. First, tau may exit host cells, transfer between 
cells, gain access to new cells, and create patholo-
gy within these cells [47]. Second, by analogy with 
the scrapie form of prion protein (PrPsc), nucleation 
or seeding activity of tau may result in a core of an 
NCI of transferred tau surrounded by additional lay-
ers of cytoplasmic tau contributed by the host cell. 
Third, the  spatial patterns of  NCI in all three sub-
types exhibited a  similar spatial pattern to PrPsc 
deposits in CJD [11,13]. Fourth, TDP-43 is a  dimeric 
nuclear protein in which the C-terminal region exhib-
its ‘prion-like’ behaviour [49], the majority of gene 
mutations associated with frontotemporal dementia 
(FTD) and motor neuron disease (MND) being locat-
ed in this region [49]. Moreover, tandem repeats 
of the ‘prion-like’ Q/N region of TDP-43, when fused 
to additional TDP-43, can cause aggregate formation 
in neuronal and non-neuronal cell lines [24]. Fifth, 
aggregates of phosphorylated TDP-43 (pTDP-43) are 
frequently present in axons of hypoglossal and facial 
nerves and in spinal cord anterior cells in MND, con-
sistent with propagation of  the  protein [44], while 
FUS activity is found in granules in gray matter 
of  the  brain stem and spinal cord, which co-local-
ise with synaptophysin [1], consistent with transport 
of  the  protein and synaptic disconnection. Sixth, 
stress granules are foci of cytoplasmic RNA formed in 
response to stress and, among many other proteins, 
also exhibit TDP-43 and FUS immunoreactivity [17]. 
Hence, the  domains involved in the  phase separa-
tion of liquid droplets such as stress granules may be 
a precursor to aggregation and propagation of pro-
teins. Hence, cell-to-cell transfer of pathological pro-
teins along anatomical pathways may be a common 
mechanism determining cortical degeneration in 
a variety of FTLD molecular subtypes.
In conclusion, FTLD characterised by NCI express-
ing different molecular pathologies exhibit similar 
spatial patterns in the  cerebral cortex, consistent 
with an association with specific anatomical path-
ways. The data provide some support for the hypoth-
esis that a ‘prion-like’ cell-to-cell transfer of patho-
genic proteins occurs across different subtypes 
of FTLD. Different FTLD subtypes therefore may be 
amenable to similar interventions; e.g., immunother-
apy which targets extracellular pathogenic proteins 
could lead to their removal, thus preventing or slow-
ing cell-to-cell propagation [50]. 
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